Development of Therapeutics and Diagnostics for Biodefense Program

by: Michael Saunders

The National Institutes of Health, otherwise termed as NIH, is an agency operating within the United States Department of Health and Human Services that is generally responsible for financially supporting the country's biomedical and health-related research studies.

The initiatives of the NIH are all geared towards the realization its primary agency mission which is to "seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce the burdens of illness and disability."

In keeping with this mission, the National Institutes of Health, in partnership with the National Institute of Allergy and Infectious Diseases(NIAID), has established the Development of Therapeutics and Diagnostics for Biodefense Program in an attempt to seek research proposals that desire to support the development of lead candidate diagnostics or therapeutics against NIAID Category A, B, or C priority agents.

NIAID Category A, B, and C priority agents are pathogens that can be used as a biological weapon in acts of terrorism or sabotage. The examples of these pathogens are the ones that cause, anthrax, botulism, plague, smallpox, tularemia, hemorrhagic fevers, melioidosis, brucellosis, typhus fever, yellow fever, rabies, and several others.

The goal of the Development of Therapeutics and Diagnostics for Biodefense is to solicit applications from eligible participants in order to further explore the options and strategies that can lead to the treatment or diagnosis of the diseases that are mentioned above.

  (continued...)

Development of Therapeutics and Diagnostics for Biodefense Program
  Page 2

About The Author Michael Saunders is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. He also maintains Websites providing resources on artist grants and children grants.

Additional Resources

category - Health Grants

Early-Stage Innovative Technology Development for Cancer Research Program
The National Institutes of Health has collaborated with the National Cancer Institute(NCI) in order to establish Early-Stage Innovative Technology Development for Cancer Research Program, wherein both agencies intend to solicit grant applications expressing intents to conduct funded exploratory research projects that concentrate on the inception and development unique, innovative technological advances that could potentially be utilized in the study of cancer.

---

Nutrition Obesity Research Centers Grant Program
In an attempt to support this mission, the National Institutes of Health has formed a partnership with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to establish the Nutrition Obesity Research Centers Grant Program wherein both agencies intend to solicit grant applications that wish to establish core centers which will be an essential part of an integrated program of nutrition and obesity research.

---

National Science Foundation's Smart Health and Wellbeing Program
The National Science Foundation has constituted the development of the Smart Health and Wellbeing (SHB) Program wherein they intend to address scientific and technical issues that would pave the way towards the transformation of the healthcare process from being rather reactive and hospital centered into becoming preventive, proactive, evidence-based, patient-centered and focused on the wellbeing of the person rather than his/her disease.

---

National Institutes of Health funds the Improving Adherence to Treatment Regimens for HIV-Positive Adolescents and Young Adults
The National Institutes of Health has recently established a program entitled Improving Adherence to Treatment Regimens for HIV-Positive Adolescents and Young Adults wherein they intend to kick-off research studies that will create, implement, and evaluate both old and new interventions that are geared towards improving adherence to medical and behavioral regimens for HIV-positive adolescents which are 11 to 21 years old and adults who are 21 to 24 years old.

---